A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Completed · Phase 2 · NCT05227690
Conditions: Schizophrenia
At a glance
- Research payments reported, 2025
- $2.5M
- U.S. investigators named
- 20
- Sites paid
- 19
- Planned or actual enrollment
- 385
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo (drug), Emraclidine 10 mg (drug), Emraclidine 30 mg (drug)
- Dates
- Started 2022-06-30; completion 2024-08-26
- Results posted
- Yes
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
From ClinicalTrials.gov, last updated 2025-09-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2.5M in research payments for this study in 2025 (61 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- George Konis, M.D. Family Medicine · Little Rock, AR
- Christopher H. Benbow, MD Psychiatry · La Jolla, CA
- Evagelos Coskinas, M.D. Psychiatry · Costa Mesa, CA
- Haig A. Goenjian, MD Psychiatry · Long Beach, CA
- Charmaine I. Semeniuk, M.D. Psychiatry · San Diego, CA
- Stephen J. Volk, MD Psychiatry · Paramount, CA
- Edwin A. Gomez, M.D. Psychiatry · Weston, FL
- Mohammad Asim Nisar, MD Psychiatry · Okeechobee, FL
- Lourdes M. Selem, MEDICAL DOCTOR Psychiatry · Miami Lakes, FL
- Bethany B. Davis, M.D. Psychiatry · Atlanta, GA
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Guy E. Brannon, M.D. Psychiatry · Shreveport, LA
- Elia E. Acevedo Diaz, M.D Psychiatry · Gaithersburg, MD
- Joseph A. Kwentus, MD Psychiatry · Flowood, MS
- Shishuka Malhotra, M.D. Psychiatry · Canton, OH
- Scott R. Bartley, M.D. Psychiatry · Dallas, TX
- Dominick S. D'aunno, MD Internal Medicine · Houston, TX
- Mary A. Knesevich, M.D. Psychiatry · Dallas, TX
- Rajinder Shiwach, MD Psychiatry · Desoto, TX
- Kathrine E. Adams, D.O. Psychiatry · Clarksville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Insite Clinical Research LLC $358,902
- Cenexel Iresearch LLC $252,853
- Collaborative Neuroscience Research LLC $233,020
- Pillar Clinical Research LLC $208,924
- Clinical Innovations Inc $187,700
- Cbh Health LLC $173,925
- Cnri San Diego LLC $173,705
- Neuro Behavioral Clinical Research Inc $171,777
- Catalina Research Institute LLC $158,041
- Health Synergy Clinical Research LLC $138,019
- Erg Holding Company LLC $111,179
- Srsd Inc $85,391
- Pharmaseek LLC $83,205
- Precise Clinical Research Inc $43,465
- Emerge Medical Research Inc $41,076
- Lsb Research Group LLC $12,969
- Synexus Clinical Research US Inc $11,703
- Research Centers of America LLC $8,843
- Mary Ann Knesevich MD PA $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.